Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 5/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430532 | 1.00 | GNAI3 (0.41) | GNAI3GNAI1GNAO1L3MBTL1MAPT | |
| SCHEMBL4837778 | 0.78 | HSP90AA1 (0.33) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1846364 | 0.78 | LMNA (0.42) | MAPTKMT2AALDH1A1LMNAMAPK1 | |
| SCHEMBL1844792 | 0.75 | POLB (0.43) | MAPTKMT2AALDH1A1LMNAMAPK1 | |
| SCHEMBL4293606 | 0.74 | SMO (0.39) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1848137 | 0.73 | KDM4E (0.51) | KMT2AALDH1A1MAPK1TSHR | |
| SCHEMBL1847339 | 0.73 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1LMNAMAPK1 | |
| Maleic Acid SCHEMBL2882692 | 0.72 | POLB (0.42) | MAPTKMT2AALDH1A1LMNAMAPK1 | |
| Fumaric Acid SCHEMBL194797 | 0.72 | POLB (0.42) | MAPTKMT2AALDH1A1LMNAMAPK1 | |
| Maleic Acid SCHEMBL8579856 | 0.72 | MAPK8 (0.35) | MAPTMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302000-A1 | COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS | Progenicyte Therapeutics, Inc. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20210046079-A1 | COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20090087462-A1 | Use of pyrimidine derivatives for cosmetic purposes | TREMBLEY MARCELLA | 2009-04-02 | — | — | US | disclosed |
| EP-1890673-A1 | USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES | DSMIP Assets B.V. (NL) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006133876-A1 | USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES | DSM IP ASSETS B.V. (NL) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046079-A1 | COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS | PSEN1, PSEN2, NES | GNAI3 1461/4885GNAI1 1939/4885GNAO1 2156/4885 |
| US-20090087462-A1 | Use of pyrimidine derivatives for cosmetic purposes | TYMP, TYMS, UNG | GNAI3 3873/4885GNAI1 3535/4885GNAO1 2896/4885 |
| US-20230302000-A1 | COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS | NES, PSEN1, PSEN2 | GNAI3 3451/4885GNAI1 3212/4885GNAO1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.